Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial

Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study

(2010) Srihari Gopal et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of 3 Doses of Paliperidone Palmitate in Adults With Acutely Exacerbated Schizophrenia

(2010) Gahan J. Pandina et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia

(2009) S. Gopal et al.   CURRENT MEDICAL RESEARCH AND OPINION

Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study

(2009) Michelle Kramer et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

An 8-Week, Double-Blind, Randomized, Placebo-Controlled Study of Olanzapine Long-Acting Injection in Acutely Ill Patients With Schizophrenia

(2009) John Lauriello et al.   JOURNAL OF CLINICAL PSYCHIATRY

Onset and Persistence of Antipsychotic Response in Patients With Schizophrenia

(2009) Ira D. Glick et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia

(2009) Bruce J Kinon et al.   NEUROPSYCHOPHARMACOLOGY

Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia

(2009) David Hough et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements

(2009) R. W. Buchanan et al.   SCHIZOPHRENIA BULLETIN

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study

(2009) David Hough et al.   SCHIZOPHRENIA RESEARCH